Literature DB >> 10361627

A longitudinal study of changes in endometrial microvascular density in Norplant implant users.

M Hickey1, M Simbar, L Young, R Markham, P Russell, I S Fraser.   

Abstract

This study aimed to investigate the effects of the subdermal levonorgestrel contraceptive implant Norplant on endometrial vascular density at different durations of exposure, and the relationship between endometrial histology, vascular density, and bleeding patterns. A prospective controlled trial of Norplant implant users compared endometrial vascular density in biopsies taken before and after Norplant implant insertion. A total of 34 women with regular menstrual cycles requesting long-term contraception were recruited at the Sydney Centre for Reproductive Health Research, Australia. A significant increase in mean endometrial microvascular density was observed from as early as 3 weeks after insertion of Norplant implants. Vascular density was increased from a control secretory phase value of 189.6 (7.0 vessels/mm2 (+/- SEM) to 253.80 +/- 7 vessels/mm2 at 2-13 weeks of Norplant implant exposure (t ratio = 2.08, p = 0.01) and 212.7 +/- 12.9 vessels/mm2 at 14-42 weeks of exposure (t ratio = 2.03, p = 0.02). In those with atrophic endometrium, or in whom myometrium and basalis only were found in biopsies (20 of 66, 30%), mean endometrial vascular density was increased at 273.1 +/- 16.1 vessels/mm2 compared with 210.9 +/- 11.7 vessels/mm2 in other histological groups (F ratio = 9.74, p = 0.0028). Bleeding and spotting in the previous 30 days were less common in those with this histological appearance at a mean of 4.95 days compared with 8.22 days. This is the first study to assess endometrial vascular density in the early months of Norplant implant use. The findings suggest that the endometrial vasculature is profoundly altered in the early months of Norplant implant exposure when bleeding problems are most common.

Entities:  

Keywords:  Australia; Biology; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Implants; Contraceptive Methods; Developed Countries; Endometrial Effects; Endometrium; Family Planning; Genitalia; Genitalia, Female; Levonorgestrel; Longitudinal Studies; Oceania; Physiology; Research Methodology; Research Report; Studies; Urogenital System; Uterus

Mesh:

Substances:

Year:  1999        PMID: 10361627     DOI: 10.1016/s0010-7824(99)00012-8

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

1.  Long-term progestin contraceptives (LTPOC) induce aberrant angiogenesis, oxidative stress and apoptosis in the guinea pig uterus: A model for abnormal uterine bleeding in humans.

Authors:  Graciela Krikun; Irina A Buhimschi; Martha Hickey; Frederick Schatz; Lynn Buchwalder; Charles J Lockwood
Journal:  J Angiogenes Res       Date:  2010-04-27

2.  Abnormal uterine bleeding during progestin-only contraception may result from free radical-induced alterations in angiopoietin expression.

Authors:  Graciela Krikun; Hilary Critchley; Frederick Schatz; Livia Wan; Rebeca Caze; Rebecca N Baergen; Charles J Lockwood
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

3.  High dose of green tea infusion normalized spiral artery density in rats treated with the depot-medroxyprogesterone acetate.

Authors:  A S Emilda; Nora Veri; Alchalidi Alchalidi
Journal:  J Intercult Ethnopharmacol       Date:  2016-10-04

4.  In vivo effects of AZD4547, a novel fibroblast growth factor receptor inhibitor, in a mouse model of endometriosis.

Authors:  Sara Santorelli; Deborah P Fischer; Michael K Harte; Johanna Laru; Kay M Marshall
Journal:  Pharmacol Res Perspect       Date:  2021-04

5.  Development of an animal experimental model to study the effects of levonorgestrel on the human endometrium.

Authors:  M-L Alvarez Gonzalez; C Galant; F Frankenne; M Nisolle; S Labied; J-M Foidart; E Marbaix; A Béliard
Journal:  Hum Reprod       Date:  2008-12-17       Impact factor: 6.918

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.